Engineered immune cells take on tough EBV cancers in early trial
Disease control
Recruiting now
This study tests a new treatment called GP350 CAR-T cells for people with blood cancers linked to the Epstein-Barr virus that have not responded to standard therapy. About 24 participants will receive their own immune cells, modified in a lab to target the virus, after a short co…
Phase: PHASE1, PHASE2 • Sponsor: Zhimin Zhai • Aim: Disease control
Last updated May 04, 2026 16:18 UTC